IFM Investors moved on Atlas Arteria with a $6.9 billion buyout bid after the ASX-listed toll road operator indicated it would not listen to its largest shareholder and consider pursuing an expensive ...
Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
IFM Investors Sponsored by IFM Investors August 31, 2025 Harnessing Infrastructure Equity: Strategic Investments for a Changing World ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results